Physician profile
William B Smithy
NPI 1235158155
$1,614.31
in general payments reported to CMS, 2019-2025
13 companies · $221 in 2025
The $221 reported for 2025 was less than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $118 · 2021: $20.20 · 2022: $345 · 2023: $228 · 2024: $441 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $890.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $890.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $348.75 | 2022-2025 | Briviact, Fintepla |
| Stryker Corporation | $306.55 | 2024-2025 | 1788 |
| Sk Life Science, INC. | $197.30 | 2021-2024 | |
| Medtronic, INC. | $173.39 | 2024 | Signia |
| Olympus America INC. | $125.00 | 2019 | |
| Ferring Pharmaceuticals INC. | $118.03 | 2020 | |
| Thd America, INC. | $83.12 | 2023 | |
| Acell, INC. | $70.75 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $53.63 | 2022 | |
| Guard Medical INC. | $47.29 | 2024 | Npseal Large |
| Tei Biosciences INC | $45.44 | 2019 | |
| Davol INC. | $26.82 | 2025 | Phasix Mesh |
| Almatica Pharma LLC | $18.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Smithy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.